A NOVEL APPROACH TO NONTHROMBOGENIC POLYMER SURFACES

在过去的几年里，努力已经指向设计 用于预防血小板聚集的控制释放的甘草素和肝素聚合物 血液聚合物界面处的粘附和血液凝固。 目前， 前列腺素释放聚合物正在体内通过短期 动物植入 本课题对肝素和甘草素的固定化进行了尝试。 我们研究了羟基和羧基衍生物的生物活性 肝素，在特定条件下合成， 交联。 肝素经过几种化学物质修饰， 通过改变用于固定过程的间隔物长度， 固定。 AT-III亲和力和生物活性，如 通过ACT和APTT试验证明，表面固定化肝素将 测定 使用不同间隔区长度的前列腺素固定是成功的， 固定化野牡丹素稳定性和活性通过 物理和生物方法。 强效但不稳定的前列环素 不直接固定;然而，使用稳定的前体化合物， 用于固定化，并进行表面反应以产生活性， 固定化前列环素

During the past several years, efforts have been directed toward the design of controlled release prostaglandins and heparin polymers to prevent platelet adhesion and blood clotting at blood polymer interfaces. Currently, prostaglandin releasing polymers are being evaluated in vivo by short-term animal implantation. In this project, the immobilization of heparin and prostaglandins is attempted. We have studied the biological activities of hydroxyl and carboxylic derivatized heparin, synthesized under conditions to specifically prevent intermolecular cross-linking. The well characterized heparin, modified by several chemical processes is being immobilized on surfaces by varying the spacer length used in the immobilization. The AT-III affinity and biological activity, as demonstrated by ACT and APTT tests, of the surface immobilized heparin will be determined. Prostaglandin immobilization using different spacer length is successful, and the stablity and activity of immobilized prostaglandins are being determined by both physical and biological methods. The potent but labile prostacyclin could not be directly immoblized; however, the stable precursor compound is utilized for the immobilization, and a surface reaction is carried to produce active, immobilized prostacyclin.